Market Pathways editors Steve Levin and David Filmore discuss important medtech regulatory and policy developments they are looking for in 2022. In this episode, they delve into the US picture, including what to expect from Congress, FDA, and CMS. Check out the second part of the conversation, where they discuss the environments in Europe and Asia, in the next episode.
Read more about the topics discussed in these Market Pathways articles:
Pathways’ Picks for 2022: 7 Medtech Policy Issues to Watch
https://bit.ly/3JNdRUS
Q&A: AdvaMed’s Scott Whitaker on Partnering, Advocacy, and the Medtech Policy Year Ahead
https://bit.ly/3LSDx3U
Device User Fee Talks Stalled as a Deadline Approaches
https://bit.ly/3p86G1A
